Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Positive Data in Phase 1 Amira Study

May 2, 2011 10:59 am | News | Comments

Amira Pharmaceuticals, Inc. announced initial positive data from a Phase 1 clinical study of AM152, an oral, selective antagonist of the LPA1 receptor. This study positions Amira to initiate a Phase 2a trial in patients suffering from systemic sclerosis.


XEN402 Relieves Pain in PHN Trial

May 2, 2011 10:55 am | News | Comments

Xenon Pharmaceuticals Inc. announced that its novel ointment XEN402 demonstrated significant and clinically meaningful reductions in pain in patients with postherpetic neuralgia.


Abbott Granted New Andogel Approval

May 2, 2011 10:51 am | by Matthew Perrone | News | Comments

Abbott Laboratories said that it received U.S. regulatory approval for a new, more potent formulation of its testosterone gel. The gel is approved for men with hypogonadism or low testosterone.


FDA Approves Nexium for Infants

May 2, 2011 10:48 am | News | Comments

British drugmaker AstraZeneca PLC said that U.S. regulators approved an injectable version of its heartburn drug Nexium for use in infants as young as a month old.


Fitch May Downgrade J & J Rating

May 2, 2011 10:46 am | News | Comments

Fitch Ratings said it is considering downgrading certain ratings for Johnson & Johnson, citing the company's move to buy Swiss medical device maker Synthes Inc. for $21.3 billion.


No More Zerenex Trials Needed

May 2, 2011 10:43 am | News | Comments

Keryx Biopharmaceuticals Inc. said it was informed by a European Union advisory committee that if its current late-stage clinical trial is successful, that study would provide enough data to support a marketing application in the EU


Watson Selling Generic Concerta

May 2, 2011 10:40 am | News | Comments

Watson Pharmaceuticals Inc. said it has started selling an authorized generic version of Johnson & Johnson's attention deficit hyperactivity disorder drug Concerta. Watson said sales of Concerta, or methylphenidate, totaled $1.5 billion in the last year.


Teva to Buy Cephalon for $6.8B

May 2, 2011 10:38 am | by Damien Troise | News | Comments

Teva Pharmaceutical Industries Ltd. has agreed to buy Cephalon Inc. for $6.8 billion in a deal that would give the world's largest generic drug developer a range of biotechnology drugs aimed at cancer and other conditions.


Particle Imager Upgrades

May 2, 2011 8:05 am | Product Releases | Comments

A technology upgrade service from Fluid Imaging Technologies enables FlowCAM particle imaging and analysis system users to install many of the company’s latest advances on their existing models.


Nanoparticle Characterization System

May 2, 2011 8:03 am | Product Releases | Comments

NanoSight announced the release of their latest NS200 nanoparticle characterization system, which features a high sensitivity camera built into the housing of the system.


Reference Standards

May 2, 2011 8:00 am | Product Releases | Comments

Whitehouse Scientific offers a paper reviewing the development of reference standards over three decades.


QB3, Deloitte Collaborate On Bioscience Innovation

May 2, 2011 7:57 am | News | Comments

The California Institute for Quantitative Biosciences (QB3) has entered into a collaboration with Deloitte to help the institute in its efforts to convert bioscience innovation into a driver for jobs, companies and improved health in California.


Acura Pharma CEO Andrew Reddick Has Died

May 2, 2011 7:54 am | News | Comments

Acura Pharmaceuticals Inc. said that President and CEO Andrew Reddick died Thursday. He was 58.


QRxPharma Completes Enrollment of Phase 3 Safety Study

May 2, 2011 7:50 am | News | Comments

QRxPharma Limited has completed patient enrolment for Study 022, a Phase 3 trial comparing the tolerability and safety profile of MoxDuo IR to equi-analgesic doses of either morphine or oxycodone alone.


First-In-Human Dosing Commenced in Alzheimer’s Trial

May 2, 2011 7:48 am | News | Comments

Anavex Life Sciences Corp. announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.